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1. Peroxisome proliferator activator receptor (PPAR)
signalling
In this issue of the Scandinavian Journal of Pain, Okine et al.
report the analgesic action of the synthetic peroxisome proliferator
activator receptor-alpha (PPAR)  agonist WY-14643 on nocicep-
tive spinal neuronal ﬁring in a rodent model of neuropathic pain
[1]. The search for an efﬁcient treatment of neuropathic pain has
been rather challenging and the demonstration that new targets
can be found is very encouraging. PPAR is a very promising tar-
get because contrary to many other anti-nociceptive treatments,
its activation does not seem to be associated with any undesir-
able effect but rather is linked to several more broad beneﬁts. It
has been for instance, associated with lowering of inﬂammation
[2], and improvement of cognitive functions in models of cogni-
tive impairment [3]. Moreover, it was also shown not to induce
tolerance, which is a common problem in chronic pain treatment
[4].
The peroxisome proliferator-activated receptors (PPARs) are
nuclear receptors best characterized for their actions in metabolism
and oxidative stress regulation. The PPAR family includes PPAR,
PPAR/ and PPAR all of which are expressed at different levels by
microglia, astrocytes, neurons and oligodendrocytes [5]. PPARs het-
erodimerize with the Retinoid X receptor to bind DNA on the PPAR
response element (PPRE) and initiate gene transcription [6], several
co-factors like PGC1-alpha, CBP/p300, SERC1 are necessary for fur-
ther ﬁne-tuning of tissue-speciﬁc effects. PPRE is highly conserved
in different species, suggesting a fundamental role for the path-
ways it activates in a variety of fundamental biological processes.
In addition to these genomic effects, receptor-like almost instanta-
neous responses (within minutes), independent of gene activation
have also been described (reviewed in [7]), consistent with the ear-
lier ﬁnding that a fraction of the PPAR proteins is located at the cell
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membrane [8]. This novel observation added even more complexity
to the previous canonical vision on genomic PPAR signalling.
The ﬁeld of PPAR signalling has been rapidly expanding follow-
ing the discoveries of endogenous ligands and the development of
new subtype speciﬁc agonists but, till recently, it has been mostly
directed to the study of metabolic and vascular disorders [9].
2. PPAR in nociception
It has been found recently that PPAR also plays an important
anti-nociceptive role in the nervous system [4], which is clearly
demonstrated in PPAR knockout mice, by their enhanced sensi-
tivity to a range of noxious and mechanical stimuli in neuropathic
pain models [10].
This likely implies that PPAR is an activator of endoge-
nous pathways involved in limiting excessive pain signalling. The
endogenous PPAR agonist palmitoylethanolamide is able to acti-
vate and subsequently desensitize the pain transducing TRPV1
channels in the peripheral nociceptive sensory neurons [11]. This
study and others also suggests that the anti-nociceptive effect is
mediated via the rapid, non-genomic PPAR signalling pathway.
All these data present PPAR as a multifaceted candidate pathway
for the ﬁne-tuning of pain control. To date, much attention was  paid
to the role of PPAR in primary sensory neurons (peripheral nocicep-
tion), which express a plethora of pain transducing molecules such
as heat and capsaicin activated TRPV1 receptors.
Recent study by Okine et al. [1] adds new support for the role of
PPAR in pain control and identiﬁes novel spinal targets for pain
processing. The authors show that intraperitoneal administration
of the synthetic PPAR agonist WY-14643 attenuated key symp-
toms of neuropathic pain in rats. The authors also obtained original
data suggesting, unlike previous views on the peripheral role of
PPAR [8], the involvement of spinal neurons in nociceptive sig-
nal processing in spinal nerve ligation model of neuropathic pain.
The principal signiﬁcance of the latter relies on the rationale route
of drug administrations to counteract spinally located neuropathic
pain. Effective systemic administration of analgesic drugs targeting
central or spinal neurons normally protected by the brain–blood
barrier has an obvious advantage over intrathecal delivery. The
synthetic PPAR agonist WY-14643 used in this study is also
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